1. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
- Author
-
Herpers, Bram, Eppink, Berina, James, Mark I, Cortina, Carme, Cañellas-Socias, Adrià, Boj, Sylvia F, Hernando-Momblona, Xavier, Glodzik, Dominik, Roovers, Rob C, van de Wetering, Marc, Bartelink-Clements, Carina, Zondag-van der Zande, Vanessa, Mateos, Jara García, Yan, Kuan, Salinaro, Lucia, Basmeleh, Abdul, Fatrai, Szabolcs, Maussang, David, Lammerts van Bueren, Jeroen J, Chicote, Irene, Serna, Garazi, Cabellos, Laia, Ramírez, Lorena, Nuciforo, Paolo, Salazar, Ramon, Santos, Cristina, Villanueva, Alberto, Stephan-Otto Attolini, Camille, Sancho, Elena, Palmer, Hector G, Tabernero, Josep, Stratton, Michael R, de Kruif, John, Logtenberg, Ton, Clevers, Hans, Price, Leo S, Vries, Robert G J, Batlle, Eduard, Throsby, Mark, Herpers, Bram, Eppink, Berina, James, Mark I, Cortina, Carme, Cañellas-Socias, Adrià, Boj, Sylvia F, Hernando-Momblona, Xavier, Glodzik, Dominik, Roovers, Rob C, van de Wetering, Marc, Bartelink-Clements, Carina, Zondag-van der Zande, Vanessa, Mateos, Jara García, Yan, Kuan, Salinaro, Lucia, Basmeleh, Abdul, Fatrai, Szabolcs, Maussang, David, Lammerts van Bueren, Jeroen J, Chicote, Irene, Serna, Garazi, Cabellos, Laia, Ramírez, Lorena, Nuciforo, Paolo, Salazar, Ramon, Santos, Cristina, Villanueva, Alberto, Stephan-Otto Attolini, Camille, Sancho, Elena, Palmer, Hector G, Tabernero, Josep, Stratton, Michael R, de Kruif, John, Logtenberg, Ton, Clevers, Hans, Price, Leo S, Vries, Robert G J, Batlle, Eduard, and Throsby, Mark
- Abstract
Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank and paired healthy colonic mucosa samples. More than 500 therapeutic bAbs generated against Wingless-related integration site (WNT) and receptor tyrosine kinase (RTK) targets were functionally evaluated by high-content imaging to capture the complexity of PDO responses. Our drug discovery strategy resulted in the generation of MCLA-158, a bAb that specifically triggers epidermal growth factor receptor degradation in leucine-rich repeat-containing G-protein-coupled receptor 5-positive (LGR5+) cancer stem cells but shows minimal toxicity toward healthy LGR5+ colon stem cells. MCLA-158 exhibits therapeutic properties such as growth inhibition of KRAS-mutant colorectal cancers, blockade of metastasis initiation and suppression of tumor outgrowth in preclinical models for several epithelial cancer types.
- Published
- 2022